Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction

F. M. Curran; U. Bhalraam; M. Mohan; J. S. Singh; S. D. Anker; K. Dickstein; A. S. Doney; G. Filippatos; J. George; M. Metra; L. L. Ng; C. N. Palmer; N. J. Samani; D. J. van Veldhuisen; A. A. Voors; C. C. Lang; I. R. Mordi

doi:10.1002/ehf2.13424

Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction

F. M. Curran, U. Bhalraam, M. Mohan, J. S. Singh, S. D. Anker, K. Dickstein, A. S. Doney, G. Filippatos, J. George, M. Metra, L. L. Ng, C. N. Palmer, N. J. Samani, D. J. van Veldhuisen, A. A. Voors, C. C. Lang, I. R. Mordi

Research output: Contribution to journal › Article › peer-review

50 Citations (Scopus)

Abstract

Inflammation is thought to play a role in heart failure (HF) pathophysiology. Neutrophil-to-lymphocyte ratio (NLR) is a simple, routinely available measure of inflammation. Its relationship with other inflammatory biomarkers and its association with clinical outcomes in addition to other risk markers have not been comprehensively evaluated in HF patients.|We evaluated patients with worsening or new-onset HF from the BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) study who had available NLR at baseline. The primary outcome was time to all-cause mortality or HF hospitalization. Outcomes were validated in a separate HF population.|1622 patients were evaluated (including 523 ventricular ejection fraction [LVEF]

Original language	English
Pages (from-to)	3168-3179
Number of pages	12
Journal	ESC Heart Failure
Volume	8
Issue number	4
DOIs	https://doi.org/10.1002/ehf2.13424
Publication status	Published - 2021

Keywords

Heart Failure Humans Lymphocytes Neutrophils Prognosis Stroke Volume Biomarkers Heart failure Inflammation Neutrophil-to-lymphocyte ratio Outcome

Access to Document

10.1002/ehf2.13424

https://www.ncbi.nlm.nih.gov/pubmed/33998162

Cite this

Curran, F. M., Bhalraam, U., Mohan, M., Singh, J. S., Anker, S. D., Dickstein, K., Doney, A. S., Filippatos, G., George, J., Metra, M., Ng, L. L., Palmer, C. N., Samani, N. J., van Veldhuisen, D. J., Voors, A. A., Lang, C. C., & Mordi, I. R. (2021). Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 8(4), 3168-3179. https://doi.org/10.1002/ehf2.13424

@article{09a2615f17d348e89d263033cc5e7512,

title = "Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction",

abstract = "Inflammation is thought to play a role in heart failure (HF) pathophysiology. Neutrophil-to-lymphocyte ratio (NLR) is a simple, routinely available measure of inflammation. Its relationship with other inflammatory biomarkers and its association with clinical outcomes in addition to other risk markers have not been comprehensively evaluated in HF patients.|We evaluated patients with worsening or new-onset HF from the BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) study who had available NLR at baseline. The primary outcome was time to all-cause mortality or HF hospitalization. Outcomes were validated in a separate HF population.|1622 patients were evaluated (including 523 ventricular ejection fraction [LVEF] ",

keywords = "Heart Failure Humans Lymphocytes Neutrophils Prognosis Stroke Volume Biomarkers Heart failure Inflammation Neutrophil-to-lymphocyte ratio Outcome",

author = "Curran, {F. M.} and U. Bhalraam and M. Mohan and Singh, {J. S.} and Anker, {S. D.} and K. Dickstein and Doney, {A. S.} and G. Filippatos and J. George and M. Metra and Ng, {L. L.} and Palmer, {C. N.} and Samani, {N. J.} and {van Veldhuisen}, {D. J.} and Voors, {A. A.} and Lang, {C. C.} and Mordi, {I. R.}",

note = "Curran, Fraser M Bhalraam, U Mohan, Mohapradeep Singh, Jagdeep S Anker, Stefan D Dickstein, Kenneth Doney, Alexander S Filippatos, Gerasimos George, Jacob Metra, Marco Ng, Leong L Palmer, Colin N Samani, Nilesh J van Veldhuisen, Dirk J Voors, Adriaan A Lang, Chim C Mordi, Ify R 2021/5/18",

year = "2021",

doi = "10.1002/ehf2.13424",

language = "English",

volume = "8",

pages = "3168--3179",

journal = "ESC Heart Failure",

issn = "2055-5822",

publisher = "The Heart Failure Association of the European Society of Cardiology",

number = "4",

}

Curran, FM, Bhalraam, U, Mohan, M , Singh, JS, Anker, SD, Dickstein, K, Doney, AS, Filippatos, G, George, J, Metra, M, Ng, LL, Palmer, CN, Samani, NJ, van Veldhuisen, DJ, Voors, AA, Lang, CC & Mordi, IR 2021, 'Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction', ESC Heart Failure, vol. 8, no. 4, pp. 3168-3179. https://doi.org/10.1002/ehf2.13424

TY - JOUR

T1 - Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction

AU - Curran, F. M.

AU - Bhalraam, U.

AU - Mohan, M.

AU - Singh, J. S.

AU - Anker, S. D.

AU - Dickstein, K.

AU - Doney, A. S.

AU - Filippatos, G.

AU - George, J.

AU - Metra, M.

AU - Ng, L. L.

AU - Palmer, C. N.

AU - Samani, N. J.

AU - van Veldhuisen, D. J.

AU - Voors, A. A.

AU - Lang, C. C.

AU - Mordi, I. R.

N1 - Curran, Fraser M Bhalraam, U Mohan, Mohapradeep Singh, Jagdeep S Anker, Stefan D Dickstein, Kenneth Doney, Alexander S Filippatos, Gerasimos George, Jacob Metra, Marco Ng, Leong L Palmer, Colin N Samani, Nilesh J van Veldhuisen, Dirk J Voors, Adriaan A Lang, Chim C Mordi, Ify R 2021/5/18

PY - 2021

Y1 - 2021

N2 - Inflammation is thought to play a role in heart failure (HF) pathophysiology. Neutrophil-to-lymphocyte ratio (NLR) is a simple, routinely available measure of inflammation. Its relationship with other inflammatory biomarkers and its association with clinical outcomes in addition to other risk markers have not been comprehensively evaluated in HF patients.|We evaluated patients with worsening or new-onset HF from the BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) study who had available NLR at baseline. The primary outcome was time to all-cause mortality or HF hospitalization. Outcomes were validated in a separate HF population.|1622 patients were evaluated (including 523 ventricular ejection fraction [LVEF]

AB - Inflammation is thought to play a role in heart failure (HF) pathophysiology. Neutrophil-to-lymphocyte ratio (NLR) is a simple, routinely available measure of inflammation. Its relationship with other inflammatory biomarkers and its association with clinical outcomes in addition to other risk markers have not been comprehensively evaluated in HF patients.|We evaluated patients with worsening or new-onset HF from the BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) study who had available NLR at baseline. The primary outcome was time to all-cause mortality or HF hospitalization. Outcomes were validated in a separate HF population.|1622 patients were evaluated (including 523 ventricular ejection fraction [LVEF]

KW - Heart Failure Humans Lymphocytes Neutrophils Prognosis Stroke Volume Biomarkers Heart failure Inflammation Neutrophil-to-lymphocyte ratio Outcome

U2 - 10.1002/ehf2.13424

DO - 10.1002/ehf2.13424

M3 - Article

SN - 2055-5822

VL - 8

SP - 3168

EP - 3179

JO - ESC Heart Failure

JF - ESC Heart Failure

IS - 4

ER -

Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction

Abstract

Keywords

Access to Document

Fingerprint

Cite this